177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience.

Swayamjeet Satapathy,Bhagwant Rai Mittal,Ashwani Sood,Apurva Sood,Rakesh Kapoor,Rajesh Gupta,Divya Khosla

177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience.

2021

Swayamjeet Satapathy
Bhagwant Rai Mittal
Ashwani Sood
Apurva Sood
Rakesh Kapoor
Rajesh Gupta
Divya Khosla

PURPOSETo compare the efficacy and safety of 177Lu-DOTATATE plus radiosensitizing capecitabine and octreotide long-acting release (LAR) as first-line systemic therapy in advanced well-differentiate...

Keywords:

Capecitabine
first line
Internal medicine
Young adult
single institution
Neuroendocrine tumors
Oncology
long acting release
Octreotide
Systemic therapy
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations